
Indian drug major Sun Pharmaceutical Industries last week agreed to pay $550 million to New York-based Pfizer as part of…
Indian drug major Sun Pharmaceutical Industries last week agreed to pay $550 million to New York-based Pfizer as part of…
The telecom department is planning to give some bands of spectrum to mobile players through administrative allotment instead of the…
Ranbaxy Laboratories may have pleaded guilty before the US department of justice for supplying fraudulent data to that country?s Food…
The government is planning to use ?white spaces? ? unused frequencies assigned between radio or TV bands to avoid interference…
Domestic drug industry body, Indian Pharmaceutical Alliance (IPA), and global pharma major Pfizer have locked horns over intellectual property regime…
Apart from supplying fraudulent data to the US Food and Drug Administration
The Indian Pharmaceutical Alliance (IPA) has reacted sharply to Pfizer’s written testimony before the House committee on ways and mea-ns…
India has as many as 10,500 drug manufacturing units but just a few hundred inspectors to verify if these units…
Prompted by the rising incidence of mobile call drops and poor network coverage, the director general of audit (post &…
In 2007, when the total Indian pharmaceutical market was estimated to be R35,000 crore,
Home minister Sushilkumar Shinde is expected to discuss technology access and sharing
For an insurance buyer, no standalone cover is yet available for covering alternative treatments
Cellular Operators Association of India, has hardened its stance against the department of telecommunications
The final norms for telecom unified licences (UL) regime will be sent to the law ministry within a week for…
Ranbaxy Laboratories may find it tough to revive its struggling US business in the face of accepting federal charges of…
When a parliamentary committee on health had submitted in its report in May 2012 that the Drug Controller General of…
India has banned several controversial drugs, including antibiotic Gaifloxacin
When in 2002, McKinsey predicted that the Indian clinical research industry would be worth $1 billion by 2010